Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + vistusertib
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Paclitaxel + vistusertib is a combination therapy consisting of the chemotherapeutic agent paclitaxel and the targeted small molecule inhibitor vistusertib. Paclitaxel is a microtubule-stabilizing agent that disrupts cell division by inhibiting microtubule depolymerization, leading to mitotic arrest and apoptosis in cancer cells. Vistusertib (AZD2014) is an oral dual inhibitor of mTOR complexes 1 and 2 (mTORC1/2), which are key regulators of cell growth, proliferation, survival, and resistance mechanisms in cancer. The combination has been investigated primarily for platinum-resistant high-grade serous ovarian carcinoma (PR-HGSC) and squamous non-small cell lung cancer (SqNSCLC). Early-phase clinical trials demonstrated manageable toxicity profiles with evidence of tumor shrinkage in both ovarian and lung cancers; however, larger randomized studies did not show significant improvement in progression-free or overall survival compared to standard chemotherapy alone[1][3][4][6].
- Other names
- paclitaxel and vistusertibweekly paclitaxel plus vistusertib
02
Targets
Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + vistusertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + vistusertib.